Our analysis summarizes baseline subject demographics , distribution of baseline pathogens isolated from blood cultures , clinical response rates at Day @ , and clinical cure rates at end of therapy and test of cure ( @ to @ days after end of therapy ) in subjects with bacteremic CABP in the ceFtarOline Community-acquired pneUmonia trial vS ceftriaxone in hospitalized patients ( FOCUS ) studies .